La Jolla Pharmaceutical Stock Price, News & Analysis (NASDAQ:LJPC)

$31.23 1.03 (3.41 %)
(As of 01/22/2018 11:15 AM ET)
Previous Close$30.20
Today's Range$29.75 - $31.33
52-Week Range$16.71 - $39.28
Volume292,600 shs
Average Volume415,815 shs
Market Capitalization$707.65 million
P/E Ratio-6.12
Dividend YieldN/A
Beta1.63

About La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical logoLa Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:LJPC
CUSIPN/A
Phone+1-858-2074264

Debt

Debt-to-Equity RatioN/A
Current Ratio12.04%
Quick Ratio12.04%

Price-To-Earnings

Trailing P/E Ratio-6.12352941176471
Forward P/E Ratio-6.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$620,000.00
Price / Sales1,115.72
Cash FlowN/A
Price / CashN/A
Book Value$2.98 per share
Price / Book10.48

Profitability

Trailing EPS($5.10)
Net Income$-78,180,000.00
Net MarginsN/A
Return on Equity-88.55%
Return on Assets-78.19%

Miscellaneous

Employees105
Outstanding Shares22,150,000

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) issued its earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.24) by $0.05. View La Jolla Pharmaceutical's Earnings History.

When will La Jolla Pharmaceutical make its next earnings announcement?

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for La Jolla Pharmaceutical.

Where is La Jolla Pharmaceutical's stock going? Where will La Jolla Pharmaceutical's stock price be in 2018?

7 equities research analysts have issued 12-month price targets for La Jolla Pharmaceutical's stock. Their predictions range from $20.00 to $91.00. On average, they expect La Jolla Pharmaceutical's stock price to reach $60.17 in the next twelve months. View Analyst Ratings for La Jolla Pharmaceutical.

What are Wall Street analysts saying about La Jolla Pharmaceutical stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (11/1/2017)
  • 2. Cowen Inc analysts commented, "LJPC reported Q1 financials." (4/28/2017)
  • 3. Chardan Capital analysts commented, "We believe the results are compelling and, based on the SPA, will likely result in LJPC-501 US approval. Recall from our 24 January 2017 note where we discussed the SPA, stating with regards to the primary endpoint," (3/2/2017)
  • 4. SunTrust Banks, Inc. analysts commented, "strong" ATHOS-3 data which implies LJPC-501 could be standard-of-care in last-line CRH.Suneja commented, "We believe today's highly favorable ATHOS-3 data (primary endpoint met; positive trend in mortality) are supportive of approval in CRH, which could be at least $500MM opportunity; an NDA filing is expected in 2H17 and full data are expected in 2017 at a major medical conference and publication in a "top-tier" journal. In our view, these results provide validation for LJPC's capital-efficient strategy of developing naturally occurring peptides with well-understood biological functions for life-threatening diseases. We reiterate our Buy rating and increase our NPV-derived PT to $57 from $38." (2/27/2017)

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a increase in short interest in December. As of December 29th, there was short interest totalling 5,038,109 shares, an increase of 32.0% from the December 15th total of 3,815,677 shares. Based on an average trading volume of 848,888 shares, the days-to-cover ratio is currently 5.9 days. Currently, 24.4% of the company's shares are short sold.

Who are some of La Jolla Pharmaceutical's key competitors?

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the folowing people:

  • Kevin C. Tang, Chairman of the Board (Age 50)
  • George F. Tidmarsh M.D. Ph.D., President, Chief Executive Officer, Secretary, Director (Age 57)
  • Dennis M. Mulroy CPA, Chief Financial Officer (Age 62)
  • Jennifer A. Carver, Chief Operating Officer (Age 63)
  • James M. Rolke, Chief Scientific Officer (Age 48)
  • Lakhmir S. Chawla M.D., Chief Medical Officer (Age 46)
  • Laura L. Douglass, Independent Director (Age 52)
  • Craig A. Johnson, Independent Director (Age 56)
  • Robert Harvey Rosen, Independent Director (Age 61)

Who owns La Jolla Pharmaceutical stock?

La Jolla Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include PERCEPTIVE ADVISORS LLC (15.30%), BROADFIN CAPITAL, LLC (5.00%), BROADFIN CAPITAL, LLC (5.00%) and Schwab Charles Investment Management Inc. (0.34%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla and Laura L Douglass. View Institutional Ownership Trends for La Jolla Pharmaceutical.

Who bought La Jolla Pharmaceutical stock? Who is buying La Jolla Pharmaceutical stock?

La Jolla Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang and Lakhmir S Chawla. View Insider Buying and Selling for La Jolla Pharmaceutical.

How do I buy La Jolla Pharmaceutical stock?

Shares of La Jolla Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of La Jolla Pharmaceutical stock can currently be purchased for approximately $31.23.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $707.65 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-78,180,000.00 in net income (profit) each year or ($5.10) on an earnings per share basis. La Jolla Pharmaceutical employs 105 workers across the globe.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2074264.


MarketBeat Community Rating for La Jolla Pharmaceutical (LJPC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

La Jolla Pharmaceutical (NASDAQ:LJPC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.713.003.00
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.17$55.33$54.60$45.20
Price Target Upside: 85.41% upside75.94% upside57.74% upside32.75% upside

La Jolla Pharmaceutical (NASDAQ:LJPC) Consensus Price Target History

Price Target History for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ:LJPC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2017HC WainwrightBoost Price TargetBuy$62.00 -> $91.00LowView Rating Details
12/28/2017SunTrust BanksSet Price TargetBuy$57.00 -> $65.00LowView Rating Details
12/22/2017CowenReiterated RatingBuy$55.00MediumView Rating Details
12/22/2017Chardan CapitalReiterated RatingBuy$90.00MediumView Rating Details
12/22/2017JPMorgan Chase & Co.Reiterated RatingSellHighView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$40.00LowView Rating Details
4/30/2017Noble FinancialReiterated RatingBuyLowView Rating Details
5/24/2016Lake Street CapitalInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

La Jolla Pharmaceutical (NASDAQ:LJPC) Earnings History and Estimates Chart

Earnings by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ LJPC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
10/26/2017Q3 2017($1.24)($1.19)ViewN/AView Earnings Details
7/27/2017Q2 2017($1.13)($1.21)$0.03 millionViewN/AView Earnings Details
4/27/2017Q1 2017($1.34)($1.26)$0.17 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.20)($1.44)$0.16 million$0.09 millionViewN/AView Earnings Details
11/3/2016Q3($0.97)($1.23)$0.26 million$0.04 millionViewN/AView Earnings Details
8/8/2016Q2($0.99)($0.90)$0.25 million$0.25 millionViewN/AView Earnings Details
5/6/2016Q416($0.74)($0.96)$0.43 million$0.23 millionViewN/AView Earnings Details
2/25/2016Q4($0.72)($0.69)$0.41 millionViewN/AView Earnings Details
11/6/2015Q315($0.69)($0.70)$0.65 millionViewN/AView Earnings Details
8/7/2015Q215($0.61)($0.70)ViewN/AView Earnings Details
4/29/2015Q1 2015($0.50)($0.59)ViewN/AView Earnings Details
3/16/2015Q414($0.37)($0.45)ViewN/AView Earnings Details
11/12/2014Q314($0.42)($0.37)ViewN/AView Earnings Details
8/14/2014Q214($0.69)($0.63)ViewN/AView Earnings Details
4/30/2014Q1 2014($0.91)($0.93)ViewN/AView Earnings Details
3/31/2014($0.24)($0.07)ViewN/AView Earnings Details
11/8/2013Q3 2013($5.50)ViewN/AView Earnings Details
7/19/2013Q2 2013($7.00)ViewN/AView Earnings Details
5/13/2013Q1 2013($12.50)ViewN/AView Earnings Details
4/1/2013Q4 2012($14.00)ViewN/AView Earnings Details
11/9/2012Q3 2012($450.00)ViewN/AView Earnings Details
8/10/2012Q2 2012($33.50)ViewN/AView Earnings Details
3/30/2012Q4 2011($593.80)ViewN/AView Earnings Details
8/17/2009Q2 2009($15,500.00)ViewN/AView Earnings Details
10/31/2008Q3 2008($150,000.00)($155,000.00)ViewN/AView Earnings Details
8/4/2008Q2 2008($175,000.00)($155,000.00)ViewN/AView Earnings Details
5/1/2008Q1 2008($180,000.00)($172,000.00)ViewN/AView Earnings Details
2/28/2008Q4 2007($180,000.00)($182,000.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

La Jolla Pharmaceutical (NASDAQ:LJPC) Earnings Estimates

2018 EPS Consensus Estimate: ($2.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.20)($1.20)($1.20)
Q2 20181($1.12)($1.12)($1.12)
Q3 20181($0.82)($0.82)($0.82)
Q4 20181$0.58$0.58$0.58
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for La Jolla Pharmaceutical (NASDAQ:LJPC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.47%
Insider Trades by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)
Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2018Laura L DouglassDirectorSell10,000$32.32$323,200.006,000View SEC Filing  
12/27/2018Jennifer CarverCOOBuy1,000$33.22$33,220.004,500View SEC Filing  
12/29/2017Laura L DouglassDirectorSell10,000$32.32$323,200.00View SEC Filing  
12/27/2017Jennifer CarverCOOBuy1,000$33.22$33,220.004,500View SEC Filing  
3/23/2017Kevin C TangDirectorBuy149,254$33.50$5,000,009.00View SEC Filing  
3/3/2017Dennis MulroyCFOBuy500$33.95$16,975.00500View SEC Filing  
3/3/2017George F TidmarshCEOBuy3,000$34.17$102,510.001,353,086View SEC Filing  
3/3/2017Lakhmir S ChawlaInsiderBuy1,600$34.80$55,680.001,085View SEC Filing  
9/13/2016Kevin C TangDirectorBuy139,035$19.82$2,755,673.70View SEC Filing  
3/4/2016Kevin C TangDirectorBuy20,000$19.85$397,000.00View SEC Filing  
3/1/2016George F TidmarshCEOBuy2,000$16.57$33,140.001,424,086View SEC Filing  
9/28/2015Lakhmir S ChawlaInsiderBuy485$27.75$13,458.75485View SEC Filing  
9/10/2015Kevin C TangDirectorBuy80,000$38.00$3,040,000.00View SEC Filing  
8/21/2015Kevin C TangDirectorBuy170,000$27.11$4,608,700.00View SEC Filing  
6/26/2015Kevin C TangDirectorBuy110,000$23.58$2,593,800.00View SEC Filing  
6/24/2015Kevin C TangDirectorBuy220,000$22.23$4,890,600.00View SEC Filing  
6/23/2015Kevin C TangDirectorBuy53,836$22.27$1,198,927.72View SEC Filing  
6/22/2015Kevin C TangDirectorBuy77,850$21.41$1,666,768.50View SEC Filing  
5/13/2015Kevin C TangDirectorBuy190,583$18.24$3,476,233.92View SEC Filing  
5/12/2015George F TidmarshCEOBuy4,000$18.37$73,480.00View SEC Filing  
12/15/2014Kevin C TangDirectorBuy232,343$12.84$2,983,284.12View SEC Filing  
12/11/2014George F TidmarshCEOBuy4,000$11.38$45,520.00View SEC Filing  
9/26/2014George F TidmarshCEOBuy2,000$9.35$18,700.00View SEC Filing  
9/26/2014Kevin C TangDirectorBuy169,555$9.14$1,549,732.70View SEC Filing  
9/25/2014Kevin C TangDirectorBuy30,500$9.17$279,685.00View SEC Filing  
9/24/2014Kevin C TangDirectorBuy95,000$9.10$864,500.00View SEC Filing  
9/18/2014George F TidmarshCEOBuy5,000$9.18$45,900.00View SEC Filing  
7/23/2014George F TidmarshCEOBuy19,000$10.50$199,500.00View SEC Filing  
5/21/2014George TidmarshCEOBuy12,000$7.37$88,440.001,391,086View SEC Filing  
4/14/2014George TidmarshCEOBuy8,000$9.53$76,240.001,391,086View SEC Filing  
2/7/2014George F TidmarshCEOBuy3,000$7.25$21,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

La Jolla Pharmaceutical (NASDAQ LJPC) News Headlines

Source:
DateHeadline
La Jolla Pharmaceutical (LJPC) Forecasted to Earn FY2022 Earnings of $3.75 Per ShareLa Jolla Pharmaceutical (LJPC) Forecasted to Earn FY2022 Earnings of $3.75 Per Share
www.americanbankingnews.com - January 18 at 11:58 PM
-$1.25 EPS Expected for La Jolla Pharmaceutical (LJPC) This Quarter-$1.25 EPS Expected for La Jolla Pharmaceutical (LJPC) This Quarter
www.americanbankingnews.com - January 16 at 9:24 PM
Short Interest in La Jolla Pharmaceutical (LJPC) Increases By 32.0%Short Interest in La Jolla Pharmaceutical (LJPC) Increases By 32.0%
www.americanbankingnews.com - January 12 at 3:14 AM
La Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Buy" from BrokeragesLa Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 5 at 3:28 PM
La Jolla Pharmaceutical (LJPC) Director Laura L. Douglass Sells 10,000 SharesLa Jolla Pharmaceutical (LJPC) Director Laura L. Douglass Sells 10,000 Shares
www.americanbankingnews.com - January 4 at 12:22 AM
Laura L. Douglass Sells 10,000 Shares of La Jolla Pharmaceutical (LJPC) StockLaura L. Douglass Sells 10,000 Shares of La Jolla Pharmaceutical (LJPC) Stock
www.americanbankingnews.com - January 4 at 12:22 AM
La Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating BenchmarkLa Jolla Pharmaceutical Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - January 3 at 5:09 PM
La Jolla Pharmaceutical (LJPC) COO Acquires $33,220.00 in StockLa Jolla Pharmaceutical (LJPC) COO Acquires $33,220.00 in Stock
www.americanbankingnews.com - January 1 at 5:26 AM
-$1.25 Earnings Per Share Expected for La Jolla Pharmaceutical (LJPC) This Quarter-$1.25 Earnings Per Share Expected for La Jolla Pharmaceutical (LJPC) This Quarter
www.americanbankingnews.com - December 31 at 3:26 AM
La Jolla Pharmaceutical (LJPC) Lifted to "Sell" at ValuEngineLa Jolla Pharmaceutical (LJPC) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - December 29 at 10:10 PM
La Jolla Pharmaceutical (LJPC) COO Purchases $33,220.00 in StockLa Jolla Pharmaceutical (LJPC) COO Purchases $33,220.00 in Stock
www.americanbankingnews.com - December 29 at 7:00 PM
SunTrust Banks Reiterates $65.00 Price Target for La Jolla Pharmaceutical (LJPC)SunTrust Banks Reiterates $65.00 Price Target for La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - December 29 at 5:04 PM
La Jolla Pharmaceutical (LJPC) Given New $91.00 Price Target at HC WainwrightLa Jolla Pharmaceutical (LJPC) Given New $91.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 29 at 8:22 AM
La Jolla Pharmaceutical (LJPC) Upgraded at BidaskClubLa Jolla Pharmaceutical (LJPC) Upgraded at BidaskClub
www.americanbankingnews.com - December 28 at 11:02 PM
La Jolla Pharma Gets FDA Approval for Blood Pressure Drug - NasdaqLa Jolla Pharma Gets FDA Approval for Blood Pressure Drug - Nasdaq
www.nasdaq.com - December 28 at 3:45 PM
La Jolla Pharmaceutical Co. is trading above its 50 day moving average : LJPC-US : December 28, 2017La Jolla Pharmaceutical Co. is trading above its 50 day moving average : LJPC-US : December 28, 2017
finance.yahoo.com - December 28 at 3:45 PM
La Jolla Pharmaceutical (LJPC) Surges: Stock Moves 11.1% HigherLa Jolla Pharmaceutical (LJPC) Surges: Stock Moves 11.1% Higher
www.zacks.com - December 26 at 9:11 AM
Jefferies Group Equities Analysts Increase Earnings Estimates for La Jolla Pharmaceutical (LJPC)Jefferies Group Equities Analysts Increase Earnings Estimates for La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - December 25 at 3:02 PM
La Jolla Pharmaceutical (LJPC) Stock Rating Reaffirmed by Chardan CapitalLa Jolla Pharmaceutical (LJPC) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - December 25 at 12:38 PM
Cowen Reiterates "Buy" Rating for La Jolla Pharmaceutical (LJPC)Cowen Reiterates "Buy" Rating for La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - December 25 at 12:38 PM
La Jolla Pharma (LJPC) PT Raised to $65 at SunTrust Robinson Humphrey; Street Underestimating Giapreza ... - StreetInsider.comLa Jolla Pharma (LJPC) PT Raised to $65 at SunTrust Robinson Humphrey; Street Underestimating Giapreza ... - StreetInsider.com
www.streetinsider.com - December 22 at 8:45 PM
FDA Approves La Jolla Pharmaceuticals (LJPC) Giapreza for Dangerously Low Blood Pressure - StreetInsider.comFDA Approves La Jolla Pharmaceutical's (LJPC) Giapreza for Dangerously Low Blood Pressure - StreetInsider.com
www.streetinsider.com - December 22 at 8:45 PM
Heres Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today - Motley FoolHere's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today - Motley Fool
www.fool.com - December 22 at 8:45 PM
Here's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher TodayHere's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today
finance.yahoo.com - December 22 at 8:45 PM
What the Latest Approval Means for La Jolla PharmaceuticalWhat the Latest Approval Means for La Jolla Pharmaceutical
finance.yahoo.com - December 22 at 8:45 PM
Christmas Comes Early For These 5 Biotechnology StocksChristmas Comes Early For These 5 Biotechnology Stocks
finance.yahoo.com - December 22 at 8:45 PM
La Jolla Pharmaceutical (LJPC) Given "Sell" Rating at J P Morgan Chase & CoLa Jolla Pharmaceutical (LJPC) Given "Sell" Rating at J P Morgan Chase & Co
www.americanbankingnews.com - December 22 at 2:20 PM
Heres Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher TodayHere's Why La Jolla Pharmaceutical Shares Are Surging 12.5% Higher Today
www.fool.com - December 22 at 12:57 PM
La Jolla Pharmaceutical (LJPC) to Post Q1 2018 Earnings of ($1.20) Per Share, Jefferies Group ForecastsLa Jolla Pharmaceutical (LJPC) to Post Q1 2018 Earnings of ($1.20) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - December 22 at 10:41 AM
FDA Approves La Jolla Pharmaceuticals (LJPC) Giapreza for Dangerously Low Blood PressureFDA Approves La Jolla Pharmaceutical's (LJPC) Giapreza for Dangerously Low Blood Pressure
www.streetinsider.com - December 22 at 9:52 AM
La Jolla stock jumps 16% after FDA approvalLa Jolla stock jumps 16% after FDA approval
finance.yahoo.com - December 22 at 9:52 AM
La Jolla Pharmaceuticals (LJPC) "Buy" Rating Reiterated at SunTrust BanksLa Jolla Pharmaceutical's (LJPC) "Buy" Rating Reiterated at SunTrust Banks
www.americanbankingnews.com - December 22 at 8:36 AM
La Jolla Pharmaceutical (LJPC) Stock Rating Upgraded by BidaskClubLa Jolla Pharmaceutical (LJPC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 21 at 11:26 PM
Analyst: La Jolla Pharma A Buy Ahead Of February FDA DateAnalyst: La Jolla Pharma A Buy Ahead Of February FDA Date
finance.yahoo.com - December 21 at 5:09 PM
La Jolla Pharmaceutical (LJPC) Coverage Initiated by Analysts at HC WainwrightLa Jolla Pharmaceutical (LJPC) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - December 21 at 3:50 PM
La Jolla Pharmaceutical (LJPC) Reports Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC-401 in ... - StreetInsider.comLa Jolla Pharmaceutical (LJPC) Reports Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC-401 in ... - StreetInsider.com
www.streetinsider.com - December 18 at 10:04 AM
La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary HemochromatosisLa Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis
finance.yahoo.com - December 18 at 10:04 AM
La Jolla Pharmaceutical (LJPC) Cut to "Strong Sell" at BidaskClubLa Jolla Pharmaceutical (LJPC) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - December 16 at 12:44 PM
La Jolla Pharmaceutical Target of Unusually High Options Trading (LJPC)La Jolla Pharmaceutical Target of Unusually High Options Trading (LJPC)
www.americanbankingnews.com - December 14 at 4:10 AM
La Jolla Pharmaceutical (LJPC) Expected to Announce Earnings of -$1.26 Per ShareLa Jolla Pharmaceutical (LJPC) Expected to Announce Earnings of -$1.26 Per Share
www.americanbankingnews.com - December 14 at 3:30 AM
La Jolla Pharmaceutical (LJPC) Receives Consensus Recommendation of "Hold" from AnalystsLa Jolla Pharmaceutical (LJPC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 11 at 6:46 PM
La Jolla Pharmaceutical (LJPC) Fell To Nearly A 6-Month LowLa Jolla Pharmaceutical (LJPC) Fell To Nearly A 6-Month Low
www.rttnews.com - December 11 at 10:28 AM
JPMorgan Downgrades La Jolla Pharma (LJPC) to Underweight - StreetInsider.comJPMorgan Downgrades La Jolla Pharma (LJPC) to Underweight - StreetInsider.com
www.streetinsider.com - December 10 at 5:18 PM
J P Morgan Chase & Co Lowers La Jolla Pharmaceutical (LJPC) to UnderweightJ P Morgan Chase & Co Lowers La Jolla Pharmaceutical (LJPC) to Underweight
www.americanbankingnews.com - December 8 at 11:12 PM
La Jolla Pharmaceutical (LJPC) Has Dropped To Over A 3-Month LowLa Jolla Pharmaceutical (LJPC) Has Dropped To Over A 3-Month Low
www.nasdaq.com - December 8 at 5:02 PM
Here's What's Causing Investors to Sell La Jolla Pharmaceutical Shares TodayHere's What's Causing Investors to Sell La Jolla Pharmaceutical Shares Today
finance.yahoo.com - December 8 at 5:02 PM
La Jolla Pharmaceutical Company Announces Initiation of Pivotal ... - GlobeNewswire (press release)La Jolla Pharmaceutical Company Announces Initiation of Pivotal ... - GlobeNewswire (press release)
globenewswire.com - December 4 at 5:06 PM
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta ThalassemiaLa Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
finance.yahoo.com - December 4 at 9:43 AM
La Jolla Pharmaceutical (LJPC) Downgraded to "Strong Sell" at ValuEngineLa Jolla Pharmaceutical (LJPC) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 7:58 AM
La Jolla Pharmaceutical (LJPC) and The Competition Head-To-Head ReviewLa Jolla Pharmaceutical (LJPC) and The Competition Head-To-Head Review
www.americanbankingnews.com - November 25 at 5:10 AM

SEC Filings

La Jolla Pharmaceutical (NASDAQ:LJPC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

La Jolla Pharmaceutical (NASDAQ:LJPC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

La Jolla Pharmaceutical (NASDAQ LJPC) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.